Examining eosinophils in patients with non-small cell lung cancer
PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC) (PROTEON).
This study is trying to see how eosinophils in different samples from patients with untreated non-small cell lung cancer can help predict their treatment outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Liege Academic / other |
| Locations | 1 site (Liège) |
| Trial ID | NCT05602259 on ClinicalTrials.gov |
What this trial studies
This prospective study investigates the role of eosinophils in various biological materials from patients with untreated non-small cell lung cancer (NSCLC). It aims to compare the detection of eosinophils in these materials and evaluate their prognostic and predictive significance. The study will involve interventions such as induced sputum collection, lung biopsy, bronchoalveolar lavage, and blood draws to gather necessary data. Participants will be monitored for at least six months following treatment initiation at the CHU de Liège.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with stage III-IV NSCLC who are eligible for immune checkpoint inhibitor treatment and have not previously received such therapy.
Not a fit: Patients with early-stage NSCLC or those who have previously undergone immune checkpoint inhibitor therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of eosinophils' role in NSCLC, potentially leading to improved prognostic tools and treatment strategies.
How similar studies have performed: While the specific role of eosinophils in NSCLC is still being explored, similar studies investigating immune cell profiles in cancer have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * o All stages of NSCLC * Stage III-IV NSCLC eligible for ICI treatment * 18 years or older; non pregnant women * in stage III-IV: no previous ICI and before ICI (mono- or combination therapy) initiation * Signed informed consent * Clinical, biological and radiological evaluation at the CHU de Liège for at least 6 months following treatment initiation Exclusion Criteria: * Probable noncompliance with the follow-up requirements of the study (psychiatric condition, socio-economic factors) * Inclusion in a clinical study contraindicating the enrolment in the PROTEON study
Where this trial is running
Liège
- CHU de Liège — Liège, Belgium (Recruiting)
Study contacts
- Study coordinator: Anne Sibille, MD
- Email: anne.sibille@chuliege.be
- Phone: +3243237452
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.